SCHEMBL6006563

SCHEMBL6006563

CN([C]=S)n1cnc2ccccc21

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.44
TDP1 Q9NUW8 1/20 0.42
HTT P42858 4/20 0.41
MEN1 O00255 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPK1 P28482 1/20 0.39
GAA P10253 1/20 0.38
PKM P14618 1/20 0.38
CYP11B1 P15538 4/20 0.38
CYP11B2 P19099 4/20 0.38
POLB P06746 1/20 0.38
TNF P01375 1/20 0.38
LMNA P02545 1/20 0.37
FGFR1 P11362 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6006476 0.83 SMN1; SMN2 (0.44) SMN1; SMN2TDP1HTTMEN1HPGD
SCHEMBL1663230 0.80 TDP1 (0.48) SMN1; SMN2TDP1HTTMEN1HPGD
Fluoride SCHEMBL7485384 0.74 SMN1; SMN2 (0.45) SMN1; SMN2TDP1HTTMEN1HPGD
SCHEMBL6955711 0.73 TDP1 (0.50) SMN1; SMN2TDP1HTTMEN1HPGD
SCHEMBL6596781 0.72 SMN1; SMN2 (0.44) SMN1; SMN2TDP1HTTMEN1HPGD
SCHEMBL1516437 0.71 SMN1; SMN2 (0.54) SMN1; SMN2HTTMEN1HPGDKMT2A
SCHEMBL1128585 0.71 GAA (0.66) SMN1; SMN2TDP1HTTHSD17B10GAA
SCHEMBL16448135 0.70 SMN1; SMN2 (0.49) SMN1; SMN2TDP1MEN1HPGDKMT2A
SCHEMBL3723869 0.70 AGER (0.51) SMN1; SMN2TDP1HTTMEN1HPGD
SCHEMBL23529284 0.69 CYP11B1 (0.49) SMN1; SMN2TDP1HTTMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1207161-B1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2006-01-18 EP disclosed
US-6777410-B2 SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-08-17 US disclosed
US-20040053923-A1 Novel isoindole derivatives BANYU PHARMACEUTICAL CO., LTD. 2004-03-18 US disclosed
US-6608098-B1 Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-08-19 US disclosed
EP-1207161-A1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053923-A1 Novel isoindole derivatives GPR119, SLC5A2, SLC5A1 SMN1; SMN2 4010/4885TDP1 4718/4885HTT 3195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.